Deal Details

Pharmaxo Is Acquired by Icon

Healthcare

Pharmaxo sale to Icon, a portfolio company of EQT

Summary

The Pharmaxo Group (“Pharmaxo” or the "Company") has been acquired by Icon Group (“Icon”), a portfolio company of EQT. Terms of the transaction were not disclosed. The transaction is subject to various regulatory approvals and customary closing conditions.

Baird served as exclusive financial advisor to Pharmaxo on this transaction.

About

The Pharmaxo Group is a leading specialist pharmaceutical manufacturer and healthcare provider, working with NHS Hospital Trusts across the UK. Pharmaxo is the owner of Bath ASU, Pharmaxo Healthcare and Pharmaxo Scientific. Within the group, Bath ASU produces thousands of life-changing aseptically compounded chemotherapy and immunotherapy products every week. Pharmaxo Healthcare delivers complex nurse-led infusion treatments, including oncology, in patients' homes or community clinics. Pharmaxo Scientific's R&D team improves the stability of their compounded products, providing customers with better flexibility and reduced waste. Together, the Company supports the NHS by getting high-quality, safe, medicines to some of the UK's most vulnerable patients when and where they need them. Pharmaxo is headquartered in Corsham, United Kingdom.

Icon Group is Australia's largest integrated provider of cancer care with a growing reach in New Zealand, Asia and the United Kingdom. Icon is built on a strong but simple mission - to deliver the best care possible to as many people as possible, as close to home as possible. Icon brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With a network of more than 300 doctors, over 50 cancer centres, five compounding facilities and the management of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.  Icon is headquartered in South Brisbane, Australia.

EQT is a purpose-driven global investment organization with more than EUR 67 billion in assets under management across 26 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately EUR 29 billion and more than 175,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. EQT is headquartered in Stockholm, Sweden.

Healthcare

Pharmaxo sale to Icon, a portfolio company of EQT